TNF receptor-associated factor 6 in advanced non-small cell lung cancer: Clinical and prognostic implications

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 11, 2012, Pages 1853-1863

  Liu, Hui ^a,b   Zhang, Tiantuo ^a,b   Ye, Jin ^a   Li, Hongtao ^a,b   Huang, Jing ^a,b   Li, Xiaodong ^c   Wu, Benquan ^a,b   Huang, Xubing ^b,d   Hou, Jinghui ^c  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; Chemotherapy; Lung carcinoma; Prognosis; TNF receptor associated factor

Indexed keywords

CARBOPLATIN; CD8 ANTIGEN; CISPLATIN; DOCETAXEL; FAS ANTIGEN; FAS LIGAND; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX; PROTEIN BAX; PROTEIN BCL 2; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TNF RECEPTOR-ASSOCIATED FACTOR 6; TREATMENT OUTCOME;

EID: 84870435772     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1255-6     Document Type: Article

References (31)

1. Bradley JR, Pober JS (2001) Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 20(44): 6482-6491 (Pubitemid 32977853)
2. Cejas PJ, Walsh MC, Pearce EL et al (2010) TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2. Blood 115(23): 4750-4757. doi:10.1182/blood-2009-09-242768
3. Chiffoleau E, Kobayashi T, Walsh MC et al (2003) TNF receptor-associated factor 6 deficiency during hemopoiesis induces Th2-polarized inflammatory disease. J Immunol 171(11): 5751-5759 (Pubitemid 37467190)
4. Elmetwali T, Young LS, Palmer DH (2010) CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signals. J Immunol 184(2): 1111-1120. doi:10.4049/jimmunol.0900528
5. Gangadharan C, Thoh M, Manna SK (2010) Late phase activation of nuclear transcription factor kappaB by doxorubicin is mediated by interleukin-8 and induction of apoptosis via FasL. Breast Cancer Res Treat 120(3): 671-683. doi:10.1007/s10549-009-0493-z
6. Gibbs A, Thunnissen F (2001) Histological typing of lung and pleural tumours: third edition. J Clin Pathol 54(7): 498-499. doi: 10.1136/jcp.54.7.498 (Pubitemid 32642935)
7. He L, Wu X, Siegel R, Lipsky PE (2006) TRAF6 regulates cell fate decisions by inducing caspase 8-dependent apoptosis and the activation of NF-kappaB. J Biol Chem 281(16): 11235-11249. doi:10.1074/jbc.M508779200 (Pubitemid 43855549)
8. Hirata Y, Ohmae T, Shibata W et al (2006) MyD88 and TNF receptor-associated factor 6 are critical signal transducers in Helicobacter pylori-infected human epithelial cells. J Immunol 176(6): 3796-3803 (Pubitemid 43364028)
9. Jundi M, Nadiri A, Al-Zoobi L, Hassan GS, Mourad W (2012) CD40-mediated cell death requires TRAF6 recruitment. Immunobiology 217(3): 375-383. doi:10.1016/j.imbio.2011.07.007
10. King CG, Kobayashi T, Cejas PJ et al (2006) TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med 12(9): 1088-1092. doi:10.1038/nm1449 (Pubitemid 44353391)
11. Kobayashi T, Walsh PT, Walsh MC et al (2003) TRAF6 is a critical factor for dendritic cell maturation and development. Immunity 19(3): 353-363. doi:10.1016/S1074-7613(03)00230-9 (Pubitemid 37153412)
12. Kobayashi T, Walsh MC, Choi Y (2004) The role of TRAF6 in signal transduction and the immune response. Microbes Infect 6(14): 1333-1338. doi:10.1016/j.micinf.2004.09.001 (Pubitemid 39539732)
13. Lee NK, Lee SY (2002) Modulation of life and death by the tumor necrosis factor receptor-associated factors (TRAFs). J Biochem Mol Biol 35(1): 61-66 (Pubitemid 35216582)
14. Li F, Sethi G (2010) Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 1805(2): 167-180. doi:10.1016/j.bbcan. 2010.01.002
15. Liu H, Zhang T, Li X et al (2008) Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer. Cancer Sci 99: 2185-2192. doi:10.1111/j. 1349-7006.2008.00922.x
16. Ma Y, Aymeric L, Locher C et al (2011a) Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 208(3): 491-503. doi:10.1084/jem.20100269
17. Ma T, Wang N, Su Z et al (2011b) Characterization of apoptosis and proliferation in esophageal carcinoma EC109 cells following siRNA-induced down-regulation of TRAF6. Mol Cell Biochem 352(1-2): 77-85. doi:10.1007/s11010- 011-0741-5
18. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1): 207-214 (Pubitemid 11167383)
19. Paik JH, Jang JY, Jeon YK et al (2011) MicroRNA-146a downregulates NFκB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. Clin Cancer Res 17(14): 4761-4771. doi: 10.1158/1078-0432.CCR-11-0494
20. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF (2007) Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 27(2): 334-348. doi: 10.1016/j.immuni.2007.05.020 (Pubitemid 47284914)
21. Rajandram R, Bennett NC, Morais C, Johnson DW, Gobe GC (2012) Renal cell carcinoma: resistance to therapy, role of apoptosis, and the prognostic and therapeutic target potential of TRAF proteins. Med Hypotheses 78(2): 330-336. doi:10.1016/j.mehy.2011.11.014
22. Rowland SL, Tremblay MM, Ellison JM, Stunz LL, Bishop GA, Hostager BS (2007) A novel mechanism for TNFR-associated factor 6-dependent CD40 signaling. J Immunol 179(7): 4645-4653
23. Santarpia M, Magri I, Sanchez-Ronco M et al(2011) mRNA expression levels and genetic status ofgenes involved in the EGFR and NF-κB pathwaysin metastatic non-small-cell lungcancer patients. J Transl Med 9:163. doi:10.1186/1479-5876-9-163
24. Shimo Y, Yanai H, Ohshima D et al (2011) TRAF6 directs commitment to regulatory T cells in thymocytes. Genes Cells 16(4): 437-447. doi:10.1111/j.1365-2443.2011.01500.x
25. Siervo-Sassi RR, Marrangoni AM, Feng X et al (2003) Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett 190(1): 61-72. doi:10.1016/S0304-3835(02)00579-7 (Pubitemid 36106557)
26. Starczynowski DT, Lockwood WW, Deléhouzée S et al (2011) TRAF6 is an amplified oncogene bridging the RAS and NF-kB pathways in human lung cancer. J Clin Invest 121(10): 4095-4105. doi:10.1172/JCI58818
27. Starska K, Forma E, Lewy-Trenda I et al (2009) The expression of SOCS1 and TLR4-NFkappaB pathway molecules in neoplastic cells as potential biomarker for the aggressive tumor phenotype in laryngeal carcinoma. Folia Histochem Cytobiol 47(3): 401-410. doi:10.2478/v10042-009-0075-2
28. Trauzold A, Röder C, Sipos B et al (2005) CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J 19(6): 620-622. doi:10.1096/fj.04-2984fje (Pubitemid 40471264)
29. Zapata JM, Krajewska M, Krajewski S et al (2000) TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol 165(9): 5084-5096
30. Zapata JM, Lefebvre S, Reed JC (2007) Targeting TRAfs for therapeutic intervention. Adv Exp Med Biol 597: 188-201. doi: 10.1007/978-0-387-70630-6-15
31. Zheng M, Morgan-Lappe SE, Yang J et al (2008) Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Res 68(18): 7570-7578. doi: 10.1158/0008-5472.CAN-08-0632